Skip to main content

Advertisement

SpringerLink
Log in

Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

  • Letter to the Editor
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

The Original Article was published on 22 February 2015

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lam L, McAndrew N, Yee M, et al. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826:199–208.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Zhou J, Peng Z, Liu Y, et al. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol. 2015;50:955–61.

    Article  CAS  PubMed  Google Scholar 

  3. Hyodo I. Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer? Gastric Cancer. 2012;15:115–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, University of Tsukuba, Tsukuba, Japan

    Takeshi Yamada, Yoshiyuki Yamamoto, Toshikazu Moriwaki & Ichisnosuke Hyodo

Authors
  1. Takeshi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshikazu Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ichisnosuke Hyodo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Yamada.

Ethics declarations

Conflict of interest

Ichinosuke Hyodo has received lecture fees from Chugai and Taiho Pharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamada, T., Yamamoto, Y., Moriwaki, T. et al. Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?. J Gastroenterol 51, 506–507 (2016). https://doi.org/10.1007/s00535-016-1184-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-016-1184-2

Keywords

Search

Navigation